Medicure has reported that a Phase II study of its lead cardioprotective drug, MC-1, is the focus of an article in the journal Expert Opinion on Investigational Drugs.
MC-1's cardioprotective efficacy was demonstrated in a Phase II MEND-1 study in patients undergoing percutaneous coronary interventions and is currently being evaluated in the large Phase II/III MEND-CABG study in patients undergoing coronary artery bypass graft surgery.
MC-1 is a naturally occurring small molecule that reduces the amount of damage to the heart following ischemia and/or ischemic reperfusion injury. Studies with MC-1 suggest that it does this by protecting cardiomyocytes (heart muscle cells). Since cardiomyocytes are essential for normal heart function and do not regenerate themselves following an ischemic event, their preservation is key to minimizing ischemic damage and maintaining proper heart function.